Asymmetrex Presents the Value of Tissue Stem Cell Counting For Supplying Stem Cell Clinical Trials and Drug Development Clinical Trials

On September 30, stem cell biotechnology company Asymmetrex presented at the 2020 Outsourcing in Clinical Trials USA Virtual Conference. In addition to discussing the value of tissue stem cell counting for better practices in stem cell and gene therapy clinical trials, Asymmetrex director James Sherley also highlighted value that stem cell counting technologies can impart

Asymmetrex Director Interviewed by Tech Company News About Recent Grant Award

Asymmetrex recently received a $0.42 million award from the NIH-National, Heart, Lung, and Blood Institute to support technical development and commercialization of its first-in-kind technology for specific and accurate counting of therapeutic tissue stem cells. Tech Company News reached out to Asymmetrex Director James L. Sherley to interview him about this achievement and how the

How Can We Outsource Stem Cell Clinical Trials Without Counting Tissue Stem Cells

Asymmetrex Receives $0.42 Million Award from the NIH-National Heart, Lung, and Blood Institute to Develop the AlphaSTEM Test™ for Stem Cell Therapies and Drug Evaluations

On September 19, 2020, stem cell biotechnology company Asymmetrex was awarded a research and development grant from the NIH-NHLBI. The $0.42 million grant was awarded to support the company’s technical development and commercialization of its first-in-kind technology for specific and accurate counting of therapeutic tissue stem cells. On the heals of Asymmetrex’s recently published peer-reviewed report describing its development

Asymmetrex Reports the First Quantitation of “True” Tissue Stem Cells In Stem Cell History

In a recent report published in the journal OBM Transplantation, stem cell biotechnology company Asymmetrex reported the first counts of therapeutic “true” tissue stem cells in the history of stem cell science and medicine. This crucial research and clinical data, long-needed for accelerating the development of new and better stem cell medicines, is now readily

New Report Begins a New Era of Stem Cell Science and Medicine: Stem Cell Biotechnology Company Asymmetrex Tells How It Counts Therapeutic Tissue Stem Cells

In an August 28 special issue of the peer-reviewed online journal OBM Transplantation, stem cell biotechnology company Asymmetrex has now published a report describing how its technology for determining the specific dosage of therapeutic tissue stem cells works. The new technology is poised to revolutionize stem cell science and stem cell medicine by giving the

Learn How to Get a Tissue Stem Cell Count Easily

Asymmetrex’s Plan for Free Stem Cell Counting Is The Feature Story by Superb Crew News

This week, Massachusetts stem cell biotechnology company Asymmetrex was the feature news story by online business and technology news platform Superb Crew. The attraction for the choice of Asymmetrex is the company’s recent announcement of its plan to begin offering free tissue stem cell counting to the stem cell research, stem cell medicine, and pharmaceutical

Asymmetrex Announces Plans to Provide Free Tissue Stem Cell Counting

Today, June 16, Massachusetts stem cell biotechnology company Asymmetrex announces that it will begin offering free tissue stem cell counting on its company website. Scheduled for opening July 5, Independence Day weekend in the U.S., the company’s counting site will give academic scientists, stem cell medicine physicians, tissue stem cell suppliers, and drug companies a

Asymmetrex Director Sherley Addresses the Clinical Trial Supply Industry About the Benefits of Stem Cell Counting

May 12, 2020   In Arena International’s Clinical Trial Supply 2020 Virtual Experience online conference, Asymmetrex Director James Sherley discussed unique challenges in the supply chain of therapies for stem cell transplantation medicine, gene therapy, and gene-editing therapy that can be readily addressed by greater use of tissue stem cell counting technologies like those developed